Lupus Erythematosus, Systemic: all 1,222 studies
Page 4 of 13. Open to participants first (399), then studies with results posted, then the rest; newest registration first within each.
- The Effect of Listening to Qur'an Recital on Quality of Life in Systemic Lupus Erythematosus PatientsRecruitingNCT06263764Not applicable
- Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus ErythematosusRecruitingNCT06261021Phase 2
- (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLERecruitingNCT06255743Not applicable
- A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyRecruitingNCT06249438Phase 1
- Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.Not yet recruitingNCT06228222
- The Role of Some Hematological Parameters in Juvenile Systemic Lupue ErythematosusNot yet recruitingNCT06227559
- fMRI Study of Early Brain Injury in Systemic Lupus ErythematosusRecruitingNCT06226324
- Anemia in Systemic Lupus Erythematosus Specially Refractory TypeNot yet recruitingNCT06210295
- Brief Pain Exposure Therapy (BPET) For Nociplastic PainRecruitingNCT06208514Not applicable
- MB-CART19.1 in Refractory SLERecruitingNCT06189157Phase 1/2
- Effects of High-intensity Interval Training in Patients With Systemic Lupus ErythematosusRecruitingNCT06166199Not applicable
- Assessment of Lipid Profile in Juvenile Systemic Lupus ErythematosusRecruitingNCT06151990
- Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus ErythematosusRecruitingNCT06137053
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingNCT06133972Phase 3
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusRecruitingNCT06121297Phase 1/2
- AntiDFS70 Lupus NephritisRecruitingNCT06119763
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus ErythematosusRecruitingNCT06106906Phase 1/2
- A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus ErythematosusRecruitingNCT06106893Phase 1/2
- Pulmonary Disease Among Patients With Systemic Lupus ErythematosusEnrolling by invitationNCT06087523
- Autotaxin as Abiomarker in Systemic Lupus Erythematosus PatientsNot yet recruitingNCT06063668
- Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus ErythematosusRecruitingNCT06032923Phase 1/2
- An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus ErythematosusRecruitingNCT06010472Early Phase 1
- Immunogenicity, Reactogenicity of Shingrix in SLERecruitingNCT06001606Phase 3
- Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus ErythematosusRecruitingNCT05988216Not applicable
- Systemic Lupus ErythematosusRecruitingNCT05984316Not applicable
- Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus PatientsRecruitingNCT05971498
- JMKX000189 for Moderate to Severe Active Systemic Lupus ErythematosusRecruitingNCT05967520Phase 2
- the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus PatientsNot yet recruitingNCT05964751
- Lupus Landmark Study: A Prospective Registry and BiorepositoryRecruitingNCT05934149
- CNCT19 Cell Injection for Refractory Systemic Lupus ErythematosusEnrolling by invitationNCT05930314Early Phase 1
- Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With ThrombocytopeniaNot yet recruitingNCT05929248Phase 2
- Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic AdjustmentsRecruitingNCT05927688
- Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus ErythematosusRecruitingNCT05916781Phase 4
- Anti KU Antibodies and Its Relationship With Systemic Lupus ErythematosusRecruitingNCT05900232Not applicable
- Efficacy and Safety of Telitacicept in Early SLERecruitingNCT05899907Phase 4
- Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric LupusRecruitingNCT05880121
- Microvascular Ocular Changes of Systemic Lupus ErythematousRecruitingNCT05863689
- Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune DiseasesEnrolling by invitationNCT05859997Not applicable
- Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic LupusRecruitingNCT05859191
- Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus ErythematosusRecruitingNCT05846347Phase 1
- Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)RecruitingNCT05845593
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruitingNCT05835310Phase 3
- Anti-CD20 Antibodies for Treatment of SLE-PAHRecruitingNCT05828147Phase 4
- Effects of Stopping Hydroxychloroquine in Elderly Lupus DiseaseRecruitingNCT05799378Phase 3
- Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus ErythematosusNot yet recruitingNCT05791799Phase 2/3
- CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus ErythematosusRecruitingNCT05765006Phase 1
- LUPUS-BEST - Treat-to-target in Systemic Lupus ErythematosusRecruitingNCT05714930Not applicable
- Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)RecruitingNCT05704153Not applicable
- Systemic Lupus Erythematosus and Accelerated AgingRecruitingNCT05698173Not applicable
- Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
- Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE PatientsRecruitingNCT05666336Phase 4
- The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LNRecruitingNCT05631717Phase 3
- Mast Cells Are Involved in the Mechanism of NPSLE EpilepsyRecruitingNCT05607368
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by QuestionnairesRecruitingNCT05567198
- Safety of the Herpes Zoster Subunit Vaccine in LupusRecruitingNCT05559671Phase 4
- Screening Biomarkers for Severe Lupus Based on Multi-omics StudiesRecruitingNCT05539001
- Optimization of Glucocorticoid Taper Strategies for SLE-ITPEnrolling by invitationNCT05506033Not applicable
- Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus ErythematosusNot yet recruitingNCT05504187Phase 2
- BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT05474885Phase 1
- Disease Activity Biomarkers in Patients With Systemic Lupus ErythematosusRecruitingNCT05443516
- The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVDRecruitingNCT05440422Phase 2
- Myeloid Derived Suppressor Cells in Systemic Lupus ErythematosusNot yet recruitingNCT05424627
- Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)RecruitingNCT05394922
- A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)Enrolling by invitationNCT05352919Phase 3
- Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus ErythematosusRecruitingNCT05339217Phase 3
- Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)RecruitingNCT05193591
- Autologous Stem Cell Transplant (ASCT) for Autoimmune DiseasesRecruitingNCT05029336Phase 2
- ILD-SARDs Registry and BiorepositoryRecruitingNCT05007340
- Treatment and Clinical Outcomes Among SLE Patients in PregnancyRecruitingNCT04976465Phase 1
- A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling by invitationNCT04976322Phase 3
- A Model About the Response of Belimumab in SLENot yet recruitingNCT04893161Phase 4
- Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus PatientsRecruitingNCT04835883Phase 2
- Development of a Therapeutic Endpoint in Pediatric Rheumatologic ConditionsRecruitingNCT04833465
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruitingNCT04751396
- Sirolimus Treatment Of Patients With SLENot yet recruitingNCT04736953Phase 2
- Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMFRecruitingNCT04702256Phase 3
- Belimumab in Patients With Systemic Lupus ErythematosusNot yet recruitingNCT04671706
- National Systemic Lupus Erythematosus Prospective Cohort, Saudi ArabiaRecruitingNCT04604990
- Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 CohortRecruitingNCT04534647
- Monogenic Lupus in Childhood Onset Systemic Lupus ErythematosusRecruitingNCT04532541
- Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus NephritisRecruitingNCT04449991Not applicable
- Sequential Belimumab and T-cell Based Therapy in SLERecruitingNCT04447053Phase 4
- Rheumatology Patient Registry and BiorepositoryRecruitingNCT04402086
- Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary ConsultationRecruitingNCT04320680Not applicable
- Expanded Access to UpadacitinibAvailableNCT04159597
- Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) PatientsRecruitingNCT04024306
- Mesenchymal Stromal Cells (MSC´s) in Renal LupusRecruitingNCT03917797Phase 2
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1
- Hydroxychloroquine in Systemic Lupus ErythematosusRecruitingNCT03802188
- Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem CellsRecruitingNCT03673748Phase 2
- Trial of Belimumab in Early LupusRecruitingNCT03543839Phase 4
- Meir Medical Center Rheumatologic BiobankRecruitingNCT03473912
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruitingNCT03276923
- Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific RegionRecruitingNCT03138941
- Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
- Systemic Lupus Erythematosus in Gullah HealthRecruitingNCT00756769
- Duke Lupus RegistryRecruitingNCT00512694
- Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)RecruitingNCT00198068
- Study of Systemic Lupus ErythematosusRecruitingNCT00001372
- Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)TerminatedNCT06161116Phase 2Results posted